Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00594568
First received: January 11, 2008
Last updated: September 22, 2014
Last verified: September 2014
Results First Received: November 6, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Alzheimer's Disease
Interventions: Drug: LY450139
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450319 titrated up to 140 mg orally once daily until Week 88.
100 mg LY450139 Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
140 mg LY450139 Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.

Participant Flow for 3 periods

Period 1:   Initial Treatment
    Placebo     100 mg LY450139     140 mg LY450139  
STARTED     501     507     529  
Intent-to-treat (ITT)     501 [1]   506 [2]   527 [2]
COMPLETED     189     153     121  
NOT COMPLETED     312     354     408  
Adverse Event                 51                 121                 144  
Death                 6                 11                 15  
Lost to Follow-up                 4                 1                 4  
Physician Decision                 3                 2                 4  
Protocol Violation                 2                 2                 5  
Withdrawal by Subject                 25                 31                 46  
Sponsor decision                 193                 142                 147  
Caregiver decision                 21                 36                 36  
Abnormal lab/electrocardiogram (ECG)                 7                 7                 6  
Entry criteria exclusion                 0                 1                 1  
[1] ITT population included all randomized participants (pts) who had at least 1 dose of study drug.
[2] ITT population included all randomized participants who had at least 1 dose of study drug.

Period 2:   Delayed Start
    Placebo     100 mg LY450139     140 mg LY450139  
STARTED     189     153     121  
COMPLETED     91     76     55  
NOT COMPLETED     98     77     66  
Death                 0                 0                 1  
Adverse Event                 12                 2                 2  
Withdrawal by Subject                 4                 3                 0  
Physician Decision                 0                 0                 1  
Lost to Follow-up                 0                 0                 1  
Caregiver Decision                 5                 6                 2  
Sponsor Decision                 77                 66                 59  

Period 3:   Safety Follow Up (SFU)-Optional
    Placebo     100 mg LY450139     140 mg LY450139  
STARTED     290 [1]   223 [1]   214 [2]
COMPLETED     229     168     172  
NOT COMPLETED     61     55     42  
Death                 0                 1                 0  
Adverse Event                 5                 0                 0  
Withdrawal by Subject                 12                 15                 13  
Lost to Follow-up                 2                 1                 2  
Caregiver Decision                 17                 16                 9  
No safety visit or follow up                 25                 22                 18  
[1] SFU was optional; pts entered from initial treatment and delayed start or did not enter SFU.
[2] SFU was optional, pts entered from initial treatment and delayed start or did not enter SFU.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450319 titrated up to 140 mg orally once daily until Week 88.
100 mg LY450139 Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
140 mg LY450139 Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
Total Total of all reporting groups

Baseline Measures
    Placebo     100 mg LY450139     140 mg LY450139     Total  
Number of Participants  
[units: participants]
  501     506     527     1534  
Age  
[units: years]
Mean ± Standard Deviation
  73.9  ± 8.1     73.6  ± 8.0     73.9  ± 8.5     73.8  ± 8.2  
Gender  
[units: participants]
       
Female     278     279     263     820  
Male     223     227     264     714  
Race/Ethnicity, Customized  
[units: participants]
       
Caucasian     413     428     441     1282  
African     3     6     3     12  
Hispanic     33     22     24     79  
Native American     0     0     2     2  
East Asian     47     45     51     143  
West Asian     5     5     6     16  
Region of Enrollment  
[units: participants]
       
United States     192     194     199     585  
Finland     6     8     8     22  
Spain     24     24     25     73  
Chile     17     14     12     43  
Israel     22     21     21     64  
Italy     6     5     6     17  
United Kingdom     14     20     21     55  
India     10     9     11     30  
France     15     14     14     43  
Canada     20     21     18     59  
Argentina     24     23     26     73  
Poland     12     15     18     45  
Belgium     8     5     5     18  
Australia     20     25     24     69  
Denmark     5     5     4     14  
South Africa     26     28     30     84  
Germany     29     21     27     77  
Japan     41     37     43     121  
Sweden     10     17     15     42  
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) Score [1]
[units: units on a scale]
Mean ± Standard Deviation
  22.8  ± 9.1     22.5  ± 8.9     23.1  ± 8.8     22.8  ± 8.9  
Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score [2]
[units: units on a scale]
Mean ± Standard Deviation
  60.5  ± 13.0     62.3  ± 11.6     60.5  ± 12.4     61.1  ± 12.4  
[1] ADAS‑Cog11 consists of 11 items assessing areas of function most typically impaired in AD: orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity.
[2] The ADCS-ADL Inventory Score is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant’s caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater disease severity.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

2.  Primary:   Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 16 weeks following treatment cessation ]

3.  Primary:   Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

4.  Primary:   Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 16 weeks following treatment cessation ]

5.  Secondary:   Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks   [ Time Frame: Baseline (randomization), 52 weeks ]

6.  Secondary:   Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

7.  Secondary:   Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks   [ Time Frame: Baseline (randomization), up to 76 weeks ]

8.  Secondary:   Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks   [ Time Frame: Baseline (randomization), up to 76 weeks ]

9.  Secondary:   Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks   [ Time Frame: Baseline (randomization), up to 76 weeks ]

10.  Secondary:   LY450139 Population Pharmacokinetics: Clearance of LY450139   [ Time Frame: 6 weeks, 12 weeks, and 52 weeks ]

11.  Secondary:   LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139   [ Time Frame: 6 weeks, 12 weeks, and 52 weeks ]

12.  Secondary:   Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

13.  Secondary:   Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

14.  Secondary:   Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

15.  Secondary:   Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

16.  Secondary:   Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

17.  Secondary:   Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks   [ Time Frame: Baseline (randomization), 76 weeks ]

18.  Secondary:   Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks   [ Time Frame: Baseline (randomization), up to 76 weeks ]

19.  Secondary:   Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 16 weeks following treatment cessation ]

20.  Secondary:   Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 16 weeks following treatment cessation ]

21.  Secondary:   Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 4 weeks following treatment cessation ]

22.  Secondary:   Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 4 weeks following treatment cessation ]

23.  Secondary:   Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 4 weeks following treatment cessation ]

24.  Secondary:   Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 4 weeks following treatment cessation ]

25.  Secondary:   Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug   [ Time Frame: Baseline (randomization), 4 weeks following treatment cessation ]

26.  Secondary:   Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks   [ Time Frame: Baseline (randomization), up to 76 weeks ]

27.  Secondary:   Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid   [ Time Frame: Baseline (randomization), up to 76 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
phone: 800-545-5979


No publications provided by Eli Lilly and Company

Publications automatically indexed to this study:

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00594568     History of Changes
Other Study ID Numbers: 7666, H6L-MC-LFAN, CTRI/2009/091/000090
Study First Received: January 11, 2008
Results First Received: November 6, 2013
Last Updated: September 22, 2014
Health Authority: United States: Food and Drug Administration
Argentina: Ministry of Health
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
Chile: Ministry of Health
Denmark: Danish Medicines Agency
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Germany: Federal Office for Radiation Protection
India: Drugs Controller General of India
Israel: Ministry of Health
Italy: The Italian Medicines Agency
Japan: Ministry of Health, Labor and Welfare
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
South Africa: Department of Health
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency